Promising and Minimally Invasive Biomarkers: Targeting Melanoma.

ABSTRACT: The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small molecule inhibitors. The biology of tumour evolution and heterogeneity has uncovered the current limitations associated with decoding genomic drivers based only on a single-site tumour biopsy. There is an urgent need to develop minimally invasive biomarkers that accurately reflect the real-time

SUBMITTER: Spiliopoulou P 

PROVIDER: S-EPMC10777980 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature